ArticleBiochimica et biophysica acta. Biomembranes2017
Antimicrobial peptides are degraded by the cytosolic proteases of human erythrocytes.
Article in Biochimica et biophysica acta. Biomembranes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 101 citations in OpenAlex.
- Artificial Intelligence-Driven Antimicrobial Peptide Discovery: Prediction, Generation, Mining and Optimization.Probiotics and antimicrobial proteins · 2026Review
- Antimicrobial peptides in anti-infective and immunomodulatory applications: Mechanisms, challenges, and emerging computational design.Zoological research · 2026Review
- Cooperative Oligomeric Peptide Combinations Enhance the Predicted Therapeutic Profile of SET-M33.Antibiotics (Basel, Switzerland) · 2026Article
- Engineering host‑defense peptides enhanced by artificial intelligence and nano delivery systems to overcome biofilms and antimicrobial resistance.Engineering microbiology · 2026Review
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.Antibiotics (Basel, Switzerland) · 2026Review
- Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape.Journal of clinical microbiology · 2026Review
- Impact of the Arrangement Modes of the Antimicrobial Motifs WWR-7 and its Analogs in CAMPs on Their Therapeutic Properties.Chemistry, an Asian journal · 2026Article
- Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026Review
- Photodynamic Antibacterial Nanofibers with Tunable Pro- and Antioxidant Activity via N,S-Doped Carbon Quantum Dots for Corneal Tissue Engineering.ACS applied materials & interfaces · 2025Article
- Modulating Antimicrobial Activity and Structure of the Peptide Esc(1-21) via Site-Specific Isopeptide Bond Formation.Journal of peptide science : an official publication of the European Peptide Society · 2025Article
- Antimicrobial Peptides Can Facilitate Whole Blood Safety from Bacteria: A Proof of Concept.ACS infectious diseases · 2025Article
- Bio-inspired biomaterial coating for enzyme responsive release of antimicrobial peptides.Materials today. Bio · 2025Article
- Natural Antimicrobial Peptides and Their Synthetic Analogues for Effective Oral Microflora Control and Oral Infection Treatment-The Role of Ceragenins in the Development of New Therapeutic Methods.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Membrane Activity of Melittin and Magainin-I at Low Peptide-to-Lipid Ratio: Different Types of Pores and Translocation Mechanisms.Biomolecules · 2024Article
- Prokaryotic Expression and Functional Verification of Antimicrobial Peptide LRInternational journal of molecular sciences · 2024Article
- Therapeutic Potential of Nanocarrier Mediated Delivery of Peptides for Wound Healing: Current Status, Challenges and Future Prospective.AAPS PharmSciTech · 2024Review
- Antibiotic Resistant Biofilms and the Quest for Novel Therapeutic Strategies.Indian journal of microbiology · 2024Review
- Evaluation of Novel HLM Peptide Activity and Toxicity against Planktonic and Biofilm Bacteria: Comparison to Standard Antibiotics.Current protein & peptide science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Well-studied and promising antimicrobial peptides (AMPs), with potent bactericidal activity, in vitro, have yet to have a significant impact in human medicine beyond topical applications. We previously showed that interactions of AMPs with concentrated human erythrocytes inhibit many of them, and suggested that screens and assays should be done in their presence to mimic host cell inhibition. Here, we use AMPs to characterize the activity of proteases that are associated with human erythrocytes. The representative AMPs, ARVA and indolicidin, are degraded significantly during incubation with dilute, washed erythrocytes and yield a variety of degradation products, suggesting significant exopeptidase activity. Comparison of these fragments with those obtained from incubation with serum shows that the proteolytic activity associated with cells yields unique products that are not explained by residual serum proteases. By separately testing the membrane and cytosolic fractions, we show that erythrocyte proteolytic activity is found only in the cytosol. Finally, we incubated a diverse cross-section of natural and synthetic linear AMPs with human erythrocyte cytosolic extracts and observed degradation of all of them. These results show that, in addition to cell binding, proteolysis can also contribute significantly to host cell inhibition of AMPs in vitro and possibly also in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.